Premium
Cerebrospinal Fluid Levels of Neurogranin in Parkinsonian Disorders
Author(s) -
Hall Sara,
Janelidze Shorena,
Zetterberg Henrik,
Brix Britta,
Mattsson Niklas,
Surova Yulia,
Blennow Kaj,
Hansson Oskar
Publication year - 2020
Publication title -
movement disorders
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 3.352
H-Index - 198
eISSN - 1531-8257
pISSN - 0885-3185
DOI - 10.1002/mds.27950
Subject(s) - neurogranin , dementia , parkinson's disease , cerebrospinal fluid , dementia with lewy bodies , biomarker , medicine , psychology , neuroscience , disease , chemistry , biochemistry , protein kinase c , enzyme
Background CSF concentration of neurogranin has been suggested as a biomarker for synapse dysfunction. Objectives To investigate CSF neurogranin in parkinsonian disorders compared to controls and Alzheimer's disease and the possible correlations between neurogranin and cognitive and motor impairment. Methods We included 157 patients with PD, 29 with PD with dementia, 11 with dementia with Lewy bodies, 26 with MSA, 21 with PSP, 6 with corticobasal syndrome, 47 controls, and 124 with Alzheimer's disease. CSF neurogranin was measured using two enzyme‐linked immunosorbent assays; from EUROIMMUN and the University of Gothenburg. Results We found a strong correlation between CSF neurogranin‐EI and CSF neurogranin–University of Gothenburg (R s = 0.890; P < 0.001). Neurogranin was decreased in PD, PD with dementia, MSA, and PSP compared to controls and Alzheimer's disease. Neurogranin did not correlate with motor or cognitive impairment, longitudinal decline, or progression to dementia in PD. Conclusions CSF neurogranin is decreased in parkinsonian disorders compared to controls, emphasizing the importance of synaptic dysfunction in these disorders. © 2019 International Parkinson and Movement Disorder Society